Investment Thesis
Opus Genetics is a pre-commercial biotech company with negative stockholders' equity (-$45.8M) and massive operating losses (-$14.4M on $2.2M revenue). While revenue growth is positive (29.1% YoY) and loss trends are improving YoY, the company remains operationally insolvent with $12.7M annual cash burn and no clear profitability trajectory within visible cash runway (~4.7 years).
Strengths
- Strong liquidity position with $60M cash providing substantial runway
- Revenue growing at 29.1% YoY with improving loss trends (net loss improved 13.8% YoY, EPS improved 62.8%)
- Low debt burden ($1.2M long-term debt) limiting leverage risk
Risks
- Technical insolvency: negative stockholders' equity of -$45.8M indicates liabilities exceed assets
- Massive operating losses with -665.9% operating margin and extreme cash burn of $12.7M annually
- Minimal revenue base ($2.2M) insufficient to justify current cost structure or indicate clear path to profitability
Key Metrics to Watch
- Operating cash flow trend and runway (current 4.7 years at $12.7M burn rate)
- Revenue acceleration and gross margin emergence as commercialization scales
- Operating expense reduction and path to cash flow breakeven timeline
Financial Metrics
Revenue
2.2M
Net Income
-65.5M
EPS (Diluted)
$-0.75
Free Cash Flow
-12.7M
Total Assets
66.8M
Cash
60.0M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-665.9%
Net Margin
-3,038.2%
ROE
N/A
ROA
-98.1%
FCF Margin
-590.0%
Balance Sheet & Liquidity
Current Ratio
7.13x
Quick Ratio
7.13x
Debt/Equity
N/A
Debt/Assets
131.6%
Interest Coverage
N/A
Long-term Debt
1.2M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-23T08:36:04.187572 |
Data as of: 2026-03-31 |
Powered by Claude AI